ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.
Saved in:
| Title: | ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost. |
|---|---|
| Authors: | Fisher LH; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Lazarus E; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Stieh DJ; Janssen Vaccines & Prevention, Leiden, The Netherlands., Yates N; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America., Zhang L; Duke University, Durham, North Carolina, United States of America., Sawant S; Duke University, Durham, North Carolina, United States of America., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Morris D; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Grant S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Randhawa A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Hendriks J; Janssen Vaccines & Prevention, Leiden, The Netherlands., Wegmann F; Janssen Vaccines & Prevention, Leiden, The Netherlands., Gill KM; The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Soweto, South Africa., Bekker LG; The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Gray GE; South African Medical Research Council, Cape Town, South Africa., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Martin T; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America., Tomaras G; Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.; Department of Immunology, Duke University Medical Center, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America., Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America.; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America., Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America. |
| Corporate Authors: | HVTN 100, HVTN 117/HPX2004 study teams |
| Source: | PLOS global public health [PLOS Glob Public Health] 2025 Apr 11; Vol. 5 (4), pp. e0004250. Date of Electronic Publication: 2025 Apr 11 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 9918283779606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-3375 (Electronic) Linking ISSN: 27673375 NLM ISO Abbreviation: PLOS Glob Public Health Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
